MSM Protein Technologies is an innovative early drug development company specializing in the discovery of antibody therapies targeting integral membrane proteins, particularly G protein-coupled receptors (GPCRs). The company has established a robust pipeline of first-in-class pre-clinical stage antibodies aimed at treating a variety of immunologic and oncologic diseases, including blood cancers, solid tumors, and autoimmune conditions. Their expertise in generating human antibodies against complex membrane proteins positions them as pioneers in the field, with a successful track record of collaborations with major pharmaceutical companies in drug discovery and development.

The company's unique, fully integrated antibody discovery platform is specifically designed to address the challenges associated with multi-spanning membrane proteins, which are critical yet difficult drug targets. MSM Protein Technologies has achieved a remarkable 100% success rate in generating highly specific functional monoclonal antibodies against various GPCRs. Their ongoing programs focus on developing therapeutic-quality antibodies that have the potential to become disease-modifying drugs for severe chronic diseases, with the company actively seeking co-development partners to bring these promising candidates to market.

United States

MSM Protein Technologies is a biotechnology company that specializes in early drug development with a focus on antibody discovery against integral membrane proteins, particularly GPCRs.

MSM Protein Technologies

Company Details